Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS · Delayed Price · Currency is USD
19.03
-0.29 (-1.50%)
Feb 18, 2026, 1:54 PM EST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 558.11B JPY in the quarter ending December 31, 2025, with 15.11% growth. This brings the company's revenue in the last twelve months to 2.05T, up 14.26% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
2.05T JPY
Revenue Growth
+14.26%
P/S Ratio
2.69
Revenue / Employee
103.83M JPY
Employees
19,765
Market Cap
35.18B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.89T | 284.57B | 17.77% |
| Mar 31, 2024 | 1.60T | 323.21B | 25.28% |
| Mar 31, 2023 | 1.28T | 233.59B | 22.36% |
| Mar 31, 2022 | 1.04T | 82.38B | 8.56% |
| Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
| Northwest Biotherapeutics | 937.00K |
Daiichi Sankyo Company News
- 1 day ago - BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics - Business Wire
- 14 days ago - DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo - Business Wire
- 15 days ago - DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy - Benzinga
- 16 days ago - Daiichi Sankyo Company, Limited (DSNKY) Q3 FY2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Banking on the long-term potential of oncology drugs: Daiichi Sankyo CFO - CNBC
- 19 days ago - Daiichi Sankyo GAAP EPS of ¥117.28, revenue of ¥1533.46B; reaffirms FY outlook - Seeking Alpha
- 19 days ago - Q3 2026 Daiichi Sankyo Co Ltd Earnings Presentation Transcript - GuruFocus
- 19 days ago - Daiichi Sankyo Company, Limited (DSNKY) Q3 2026 Earnings Call Transcript - Seeking Alpha